Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp
Start free

Bioventus Inc. (BVS) Cash Flow Statement

Bioventus Inc. (BVS) generated $96.9M of operating cash flow over the twelve months to 2026-06-30, spent $2.6M on capital expenditure and had free cash flow of $94.3M, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BVSBioventus Inc.Follow BVS — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
1.3B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
10 Nov, in 16 days
LineFY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Operating cash flow0.02-0.010.020.040.070.10
Capital expenditure0.010.000.010.000.00-0.00
Free cash flow0.01-0.020.010.040.070.09
Stock-based compensation0.020.020.000.010.01—

USD billions · SEC XBRL

Bioventus Inc. — questions

What is Bioventus Inc.'s operating cash flow?
$96.9M over the twelve months to 2026-06-30.
How much does Bioventus Inc. spend on capital expenditure?
$2.6M over the twelve months to 2026-06-30.
What is Bioventus Inc.'s free cash flow?
$94.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.

Every figure on this page comes from Bioventus Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.